Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
LQDA(NASDAQ:LQDA) MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium taking place September 18 – 20, 2025, in Seattle.
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
LQDAMORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Boston.
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
LQDAMORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on August 12, 2025, to review financial performance and provide a corporate update.
Wells Fargo Maintains Overweight on Liquidia, Raises Price Target to $25
LQDALiquidia Begins Shipping Newly Approved Yutrepia for Rare Lung Diseases Just Days After FDA OK
LQDANeedham Maintains Buy on Liquidia, Raises Price Target to $32
LQDAScotiabank Maintains Sector Outperform on Liquidia, Raises Price Target to $37
LQDAThese Analysts Boost Their Forecasts On Liquidia
LQDAWells Fargo Maintains Overweight on Liquidia, Raises Price Target to $23
LQDABreaking Down Liquidia: 12 Analysts Share Their Views
LQDAHC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $35
LQDANeedham Reiterates Buy on Liquidia, Maintains $25 Price Target
LQDALiquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge
LQDALiquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics
Trading Halt: Halt status updated at 2:50:00 PM ET: Quotation Resumption: News and Resumption Times
LQDALiquidia Secures FDA Approval For YUTREPIA Inhalation Powder, Prostacyclin Analog For Adults With PAH And Pulmonary Hypertension Associated With ILD To Improve Exercise Ability
LQDATrading Halt: Halted at 1:52:20 p.m. ET - Trading Halt: Halt News Pending
LQDANeedham Reiterates Buy on Liquidia, Maintains $25 Price Target
LQDAOppenheimer Downgrades Liquidia to Underperform, Announces $13 Price Target
LQDANeedham Reiterates Buy on Liquidia, Maintains $25 Price Target
LQDAWhere Liquidia Stands With Analysts
LQDAHC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
LQDAUnited Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.
LQDARaymond James Maintains Strong Buy on Liquidia, Raises Price Target to $29
LQDALiquidia Q1 EPS $(0.45) Misses $(0.41) Estimate, Sales $3.12M Miss $3.27M Estimate
LQDAScotiabank Maintains Sector Outperform on Liquidia, Raises Price Target to $36
LQDAReported Friday, Liquidia Clears Legal Hurdle As Court Dismisses United Therapeutics' Challenge To PH-ILD Indication
LQDABreaking Down Liquidia: 4 Analysts Share Their Views
LQDANeedham Reiterates Buy on Liquidia, Maintains $25 Price Target
LQDALiquidia Announces FDA Acceptance Of New Drug Application Resubmission For YUTREPIA Inhalation Powder
LQDAWhat 4 Analyst Ratings Have To Say About Liquidia
LQDAScotiabank Maintains Sector Outperform on Liquidia, Raises Price Target to $34
LQDAHC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
LQDANeedham Maintains Buy on Liquidia, Raises Price Target to $25
LQDALiquidia FY 2024 GAAP EPS $(1.66) Misses $(1.56) Estimate, Sales $14.00M Miss $15.88M Estimate
LQDALiquidia Enters Sixth Amendment To Agreement With HealthCare Royalty To Provide Up To Additional $100M Of Financing
LQDALiquidia Litigation Against FDA Over Tyvaso DPI Exclusivity Denied; United Therapeutics' Cross Claim Remains Pending; Exclusivity Expires May 23, 2025
LQDABreaking Down Liquidia: 4 Analysts Share Their Views
LQDANeedham Reiterates Buy on Liquidia, Maintains $19 Price Target
LQDAHC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
LQDAThe Analyst Landscape: 11 Takes On Liquidia
LQDANeedham Reiterates Buy on Liquidia, Maintains $19 Price Target
LQDA'Interesting motion by Liquidia asking the judge for a stay of enforcement of paragraph 4 of the courts final judgment pending appeal' - TradeHawk
LQDA